X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 19.8 19.9 99.4% View Chart
P/BV x 3.7 3.5 106.5% View Chart
Dividend Yield % 0.3 0.3 111.9%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
GLENMARK PHARMA
Mar-18
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs809930 87.0%   
Low Rs504517 97.4%   
Sales per share (Unadj.) Rs281.1322.6 87.1%  
Earnings per share (Unadj.) Rs41.428.5 145.2%  
Cash flow per share (Unadj.) Rs50.939.2 129.8%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.3 137.8%  
Book value per share (Unadj.) Rs199.4183.0 108.9%  
Shares outstanding (eoy) m585.88282.17 207.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.2 104.1%   
Avg P/E ratio x15.925.4 62.5%  
P/CF ratio (eoy) x12.918.5 69.9%  
Price / Book Value ratio x3.34.0 83.3%  
Dividend payout %6.07.0 86.1%   
Avg Mkt Cap Rs m384,630204,206 188.4%   
No. of employees `00017.313.7 126.4%   
Total wages/salary Rs m21,30818,718 113.8%   
Avg. sales/employee Rs Th9,500.76,636.8 143.2%   
Avg. wages/employee Rs Th1,229.41,364.7 90.1%   
Avg. net profit/employee Rs Th1,397.9586.1 238.5%   
INCOME DATA
Net Sales Rs m164,66691,031 180.9%  
Other income Rs m1,020914 111.6%   
Total revenues Rs m165,68691,945 180.2%   
Gross profit Rs m37,71816,154 233.5%  
Depreciation Rs m5,5803,019 184.8%   
Interest Rs m7772,856 27.2%   
Profit before tax Rs m32,38011,193 289.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1833,155 259.4%   
Profit after tax Rs m24,2298,039 301.4%  
Gross profit margin %22.917.7 129.1%  
Effective tax rate %25.328.2 89.7%   
Net profit margin %14.78.8 166.6%  
BALANCE SHEET DATA
Current assets Rs m121,87869,887 174.4%   
Current liabilities Rs m86,80632,879 264.0%   
Net working cap to sales %21.340.7 52.4%  
Current ratio x1.42.1 66.1%  
Inventory Days Days13081 159.5%  
Debtors Days Days6893 73.1%  
Net fixed assets Rs m81,03728,892 280.5%   
Share capital Rs m586282 207.6%   
"Free" reserves Rs m116,21851,353 226.3%   
Net worth Rs m116,80451,635 226.2%   
Long term debt Rs m4,51241,418 10.9%   
Total assets Rs m211,052125,954 167.6%  
Interest coverage x42.74.9 867.2%   
Debt to equity ratio x00.8 4.8%  
Sales to assets ratio x0.80.7 108.0%   
Return on assets %11.88.6 137.0%  
Return on equity %20.715.6 133.2%  
Return on capital %27.415.1 181.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72736,317 222.3%   
Fx outflow Rs m34,7009,720 357.0%   
Net fx Rs m46,02726,598 173.0%   
CASH FLOW
From Operations Rs m19,54816,481 118.6%  
From Investments Rs m-19,570-10,133 193.1%  
From Financial Activity Rs m8,642-4,685 -184.5%  
Net Cashflow Rs m8,9221,770 504.1%  

Share Holding

Indian Promoters % 54.1 48.3 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 6.9 115.2%  
FIIs % 27.7 34.4 80.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 56,727 122.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 12, 2018 10:51 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS